NCT01937507

Hepatic Artery Infusion With FOLFOX in Liver Metastasis From Breast Cancer

Pilot Study of Hepatic Arterial Infusion (HAI) With Oxaliplatin, Folinic Acid and 5 Fluorouracil (FOLFOX) in Heavily Pre-Treated Patients With Liver-Predominant Metastasis From Breast Cancer

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 2 (actual)
• Sponsor: Western Regional Medical Center · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Deliver oxliplatin and 5-FU via HAI to breast cancer patients with liver-only or liver-predominant metastases who have failed at least one line of systemic chemotherapy in metastatic setting.

Detailed description

In this pilot study, the investigators will deliver oxliplatin and 5-FU via HAI to breast cancer patients with liver-only or liver-predominant metastases who have failed at least one line of systemic chemotherapy in metastatic setting. The investigators hypothesize that HAI chemotherapy will be able to convert some patients to surgical resection candidates, or/and to overcome chemo-resistance of liver metastases to systemic i.v. chemotherapy for some clinically fit, heavily pre-treated patients.

Conditions

• Metastatic Breast Cancer

Interventions

Type	Name	Description
DRUG	HAI with FOLFOX	HAI with FOLFOX q 3 weeks

Timeline

• Start date: 2012-12-01
• Primary completion: 2014-07-01
• Completion: 2014-07-01
• First posted: 2013-09-09
• Last updated: 2018-02-07
• Results posted: 2017-11-08

Locations

1 site across 1 country: United States